Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis.
Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T, Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H.
Wang X, et al. Among authors: zheng b.
Cell. 2024 Sep 5;187(18):4890-4904.e9. doi: 10.1016/j.cell.2024.06.027. Epub 2024 Jul 15.
Cell. 2024.
PMID: 39013470
Clinical Trial.